
- Oncology NEWS International Vol 18 No 6
- Volume 18
- Issue 6
Abraxis backs SPARC as prognostic biomarker
SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.
SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.
Researchers at Abraxis BioScience, the manufacturer of Abraxane (nab-paclitaxel), found that recombinant human SPARC grown in vitro fostered angiogenesis and the development of mature blood vessels. SPARC may play a greater role in the angiogenic process beyond initiating the growth of new blood vessels, they said (abstracts 1478, 2572, 3769, 4017, 5168).
Articles in this issue
over 16 years ago
ADT in prostate ca increases risk of bone and heart complicationsover 16 years ago
ALK-1 receptor: New target in angiogenesisover 16 years ago
Abraxane prolongs PFS in metastatic diseaseover 16 years ago
SAVI applicator removes obstacles associated with brachytherapyover 16 years ago
Mistrust, costs reduce breast cancer screening among minoritiesover 16 years ago
Oral chemotherapy poses more challenges for cancer communityover 16 years ago
CMS nixes CT colonography screeningover 16 years ago
New ultrasound strategy helps pinpoint prostate tumorsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.